In Vitro Glycoengineering (IVGE)
In vitro glycoengineering (IVGE) technology specifically and effectively changes the type of glycosylation of biopharmaceuticals, thus affecting their biological activity. CD BioGlyco has developed an advanced Glycoengineering platform to provide clients with IVGE services to solve their problems in the development of recombinant protein drugs and monoclonal antibodies.
Glycosylation of Proteins
Glycosylation is a common post-translational modification that occurs on the side chains of many amino acid residues of proteins in many different ways. Depending on the linkage established with the protein, protein glycosylation is divided into two general types: 1) Attached of N-glycans to the nitrogen atom of the asparagine (Asn) side chain; 2) Attached of O-glycans to the oxygen atom of the serine (Ser) or threonine (Thr) side chain. Glycans bound to glycoproteins typically consist of as many as a dozen monosaccharides. These glycans interact with amino acid residues, which in turn affect protein folding efficiency and conformational stability.
Fig.1 The two most common types of protein glycosylation. (Ma, et al., 2020)
Studies have found that glycosylation affects the pharmacokinetics, pharmacodynamics, therapeutic activity, and biomanufacturing of protein therapeutics. The absorption, distribution, metabolism, and excretion of protein therapeutics are closely related to the glycosylation process. In terms of pharmacodynamics and biological activity, it has been shown that the activity of protein drugs such as recombinant human hyaluronidase depends on glycosylation. The production of protein drugs relies on glycocompatible production systems, such as the Chinese hamster ovary cell (CHO) expression system.
Glycoengineering
Glycoengineering is a method to improve protein properties by changing protein glycosylation. In the early days, scientists added or removed target sugars to proteins through in vivo genetic techniques and in vitro enzymatic methods. With the development of recent years, glycoengineering technology has not been limited to improving the properties of proteins through naturally occurring glycans and glycosidic linkages. Researchers have also applied unnatural glycans and site-selective conjugation chemistry to glycoengineering to improve the therapeutic effects of drugs.
Fig.2 Glycoengineering strategies for recombinant glycoprotein therapeutics. (Narimatsu, et al., 2021)
IVGE: Redefining Glycosylation Control
Glycoengineering has attracted more and more scientists' attention as a method to improve the efficacy of protein drugs. At CD BioGlyco, we have established an advanced IVGE platform to provide our clients with protein glycoengineering and antibody glycoengineering services. We specifically and efficiently change the type of glycosylation through IVGE technology, thereby altering the biological activity of the drug. Our protein glycoengineering strategy is mainly by changing the number and location of glycosylation sites or changing the glycan structure of individual glycosylation sites. We also provide clients with high-quality antibody remodeling, digestion, deglycosylation, and site-specific conjugation services.
- Preliminary Glycoprotein Analysis
Comprehensive glycan profiling of the client's purified glycoproteins using techniques such as mass spectrometry (MS) and liquid chromatography (LC) is performed to determine the initial glycoform profile.
- Strategic Glycan Remodeling
Based on the characterization data and the client's project goals, we will develop a specific glycosylation remodeling plan. This plan outlines the precise enzymatic reactions required to achieve the desired glycosyl structure. This may involve using glycosidases to remove existing heterogeneous glycans or using a combination of enzymes to construct new, well-defined glycosyl structures.
We offer precise modification of glycosylation on a wide range of proteins. This service enables the creation of bio-better proteins with improved half-life, enhanced stability, and modulated biological activity, all through the controlled addition or removal of glycan structures.
Our specialized antibody glycoengineering services allow for the fine-tuning of the Fc glycan to optimize effector functions. We produce antibodies with increased antibody-dependent cell-mediated cytotoxicity (ADCC) or reduced immunogenicity, which are crucial for developing next-generation immunotherapies.
- In Vitro Enzymatic Reactions
Purified glycoproteins are incubated with the selected enzyme and activated glycosubstrate under optimized reaction conditions (such as temperature, pH, and cofactors). Our robust and scalable processes ensure high reaction efficiency and minimal side reactions, resulting in rapid generation of the target glycoforms.
- Purification and Separation
Following the enzymatic reaction, the modified glycoprotein is purified to remove residual enzyme, unreacted substrate, and any byproducts. We utilize state-of-the-art purification techniques, including affinity and ion exchange chromatography, to ensure the final product is highly pure and free of contaminants.
- Quality Control and Validation
A range of analytical methods, including high-resolution MS and functional analysis, is used to confirm the integrity of the protein backbone and the homogeneity of the glycan structure.
Workflow
Publication Data
Journal: Antibodies
IF: 2.7
Published: 2019
Results: This study investigates how IgG1 Fc sialylation affects antibody structure and function via hydrogen/deuterium exchange-MS (H/DX-MS) and surface plasmon resonance (SPR), using trastuzumab glyco-variants. Larger Fc glycans reduced H/DX in the Cγ2 domain, indicating greater conformational stability. α-2,6-sialylated (ST6) variants showed less deuterium uptake and enhanced FcγR binding, while α-2,3-sialylated (ST3) forms had higher H/DX and reduced receptor binding. De-glycosylated antibodies exhibited increased Cγ2 H/DX and nearly lost FcγR binding. Findings reveal that sialylation linkage (α-2,3 vs. α-2,6) differentially modulates IgG1 higher-order structure and effector function, emphasizing glycan structure's role in IgG1 conformation and FcγR interactions.
Fig.3 Study design for the impact of IgG1 Fc sialylation on backbone amide H/D exchange. (Kuhne, et al., 2019)
Applications
- Biopharmaceutical development: IVGE is essential for developing next-generation therapeutic proteins, vaccines, and antibodies with optimized safety, stability, and efficacy profiles.
- Biosimilar development: Our services help in creating biosimilars with glycan profiles that closely match or even surpass those of the reference product, ensuring comparability and functional equivalence.
- Glycobiology research: IVGE allows researchers to generate well-defined glycoprotein standards for studying the biological roles of specific glycans, including their impact on protein folding, receptor binding, and cellular signaling.
Advantages
- Our enzymatic approach enables the creation of a single, defined glycoform, eliminating the batch-to-batch variability and heterogeneity inherent in cell-based systems.
- The enzymatic reactions are robust and easily scalable, making them suitable for projects ranging from early-stage research to large-scale biopharmaceutical manufacturing.
- We enable the rational design of glycans to improve key attributes such as serum half-life, solubility, and receptor binding affinity.
Frequently Asked Questions
CD BioGlyco is a leading service provider specializing in glycoengineering services. We have established a professional IVGE platform. If you are interested in our IVGE services, please contact us for more details without any hesitation.
Associated Services
References
- Ma, B.; et al. Protein glycoengineering: An approach for improving protein properties. Frontiers in Chemistry. 2020, 8: 622. (Open Access)
- Narimatsu, Y.; et al. Genetic glycoengineering in mammalian cells. Journal of Biological Chemistry. 2021, 296. (Open Access)
- Kuhne, F.; et al. The impact of immunoglobulin G1 Fc sialylation on backbone amide H/D exchange. Antibodies. 2019, 8(4): 49. (Open Access)
Quick Links
Resources
- Glyco™ Synthesis Platform
- Custom Glycoprotein Synthesis
- Custom Glycoside Synthesis
- Custom Glycosyl Donor Synthesis
- Custom Thioglycoside Synthesis
- Custom Phosphatidylinositol Synthesis
- Custom Cyclodextrin Synthesis
- Custom Rhamnolipid Synthesis
- Custom Sphingolipid Synthesis
- Custom Building Block Synthesis
- Carbohydrate Manufacturing
- Synthesis Process Development and Optimization
- Custom Carbohydrate Synthesis
- Custom Glycolipid Synthesis
- Custom Glycopeptide Synthesis
- Custom Glycoconjugate Synthesis
- Custom Sugar-Nucleotide Synthesis
- Nucleoside & Nucleotide Synthesis Service
- Custom Oligonucleotide Synthesis Service
- Polynucleotide Synthesis Service
- Nucleoside & Nucleotide Modification Service
- Oligonucleotide Modification Service
- Nucleoside-based Production Service
- Nucleotide-based Production Service
- OPME-based NDP-sugar Synthesis Service
- OPME-based NMP-sugar Synthesis Service
- Glycomics Platform
- Glycoproteomics Platform
- N-Glycoproteomics of PDX Models
- Nanotechnologies for the Detection of Glycopeptides
- Glycoprotein Enrichment
- Glycoprotein Quantification
- Glyco-biomarker Detection Service
- Glyco-biomarker AFP Detection Service
- Glyco-biomarker CA19-9 Detection Service
- Glyco-biomarker CA125 Detection Service
- Glyco-biomarker CA15–3 Detection Service
- Glyco-biomarker CEA Detection Service
- Glyco-biomarker PSA Detection Service
- Glyco-biomarker Immunoglobulin G (IgG) Detection Service
- Glyco-biomarker Haptoglobin (Hp) Detection Service
- Glyco-biomarker α1-Antitrypsin (A1AT) Detection Service
- Glyco-biomarker α1-Acid Glycoprotein (AGP) Detection Service
- Glyco-biomarker Ceruloplasmin (CP) Detection Service
- Glyco-biomarker Fetuin A Detection Service
- Site Occupation
- Glycoprotein Structure Analysis
- Glycosylation Site-specific Antibody-Drug Conjugate (ADC) Development Platform
- Carbohydrate-based Glycomedicine Development Platform
- By Sources of Carbohydrate
- By Types of Carbohydrate
- Monosaccharides-based Glycomedicine Development
- Disaccharides-based Glycomedicine Development
- Trisaccharides-based Glycomedicine Development
- Oligosaccharides-based Glycomedicine Development
- Polysaccharides-based Glycomedicine Development
- Glycosides-based Glycomedicine Development
- Glycopeptide-based Glycomedicine Development
- Glycomimetic-based Glycomedicine Development
- By Applications of-based Glycomedicines
- Carbohydrate-based Anticoagulant Glycomedicine Development
- Carbohydrate-based Cardiovascular Glycomedicine Development
- Carbohydrate-based Antitumor Glycomedicine Development
- Carbohydrate-based Antidiabetic Glycomedicine Development
- Carbohydrate-based Antibacterial Glycomedicine Development
- Carbohydrate-based Antiviral Glycomedicines Development
- Carbohydrate-based Antiparasiti Glycomedicine Development
- By Discovery Strategies
- Glycoengineering-based Glycomedicine Development
- Production of Food Ingredients
- Multi-omics Platform for Cancer Glucose Metabolism (MOPCGM)
- Cancer Cell Glycolytic Analysis
- Cancer Cell TCA Cycle Analysis
- Cancer Cell PPP Analysis
- Gene-level Regulation Analysis of Cancer Glucose Metabolism
- Interplay Between Glucose Metabolism Reprogramming and Tumorigenesis & Progression
- Interplay Between Glucose Metabolism Reprogramming and Proliferative Signaling
- Interplay Between Glucose Metabolism Reprogramming and Growth Suppressor
- Interplay Between Glucose Metabolism Reprogramming and Cancer Cell Death
- Interplay Between Glucose Metabolism Reprogramming and Replicative Immortality
- Interplay Between Glucose Metabolism Reprogramming and Angiogenesis
- Interplay Between Glucose Metabolism Reprogramming and Invasion & Metastasis
- Interplay Between Glucose Metabolism Reprogramming and Immune Escape
- Interplay Between Glucose Metabolism Reprogramming and Genomic Instability
- Interplay Between Glucose Metabolism Reprogramming and Tumor-associated Inflammation
- Glucose Metabolism-Microenvironment Crosstalk Analysis in Cancer
- Cancer Glucose Metabolism In Vivo Analysis
- Applications of Studing Cancer Glucose Metabolism
- Discovery of Cancer Glucose Metabolism Small Molecule Inhibitor
- Discovery of Cancer Glucose Metabolism Therapeutic Monoclonal Antibodies
- Development of Gene Therapy Targeting Cancer Glucose Metabolism
- Discovery of Cancer Glucose Metabolism CAR-T Therapy Targeting
- Discovery of Cancer Glucose Metabolism Combination Therapy Strategy
- Discovery of Cancer Glucose Metabolism Precision Therapeutic Strategies
- Glycoengineering Platform
- Therapeutic Nucleic Acid Development Platform
- Therapeutic Oligonucleotide Synthesis Service
- siRNA Synthesis
- miRNA Synthesis
- ASO Synthesis
- Aptamer Synthesis
- PMO Synthesis
- sgRNA Synthesis
- Circular RNA Synthesis
- PNA Synthesis
- Lipid-based GalNac-RNA Delivery Service
- CpG Oligonucleotide Synthesis
- Click-based GalNac-RNA Delivery Service
- AntimiR Synthesis
- GalNAc-siRNA Delivery Service
- tRNA Synthesis
- GalNAc-ASO Delivery Service
- saRNA Synthesis
- Reporter Gene mRNA Synthesis
- Gene Editing mRNA Synthesis
- Gene Replacement mRNA Synthesis
- Cre Recombinase mRNA Synthesis
- hEPO mRNA Synthesis
- OVA mRNA Synthesis
- Therapeutic Oligonucleotide Modification Service
- Therapeutic Oligonucleotide Delivery Development Service
- Targeted Ligand and Linker Synthesis
- Monoantennary GalNac-RNA Delivery
- Biantennary GalNac-RNA Delivery
- Triantennary GalNac-RNA Delivery
- Tetra-antennary GalNac-RNA Delivery
- Solution Phase-based GalNac-RNA Delivery
- Solid Phase-based GalNac-RNA Delivery
- mRNA Poly(A) Tail Length Analysis
- GalNAc-siRNA Delivery
- GalNAc-ASO Delivery
- GalNAc-miRNA Delivery
- GalNAc-Aptamer Delivery
- GalNAc-AntimiR Delivery
- GalNAc-mRNA Delivery
- GalNAc-PNA Delivery
- Peptide-Therapeutic Oligonucleotide Delivery
- LNP-Therapeutic Oligonucleotide Delivery
- PEG-Therapeutic Oligonucleotide Delivery
- Biological Evaluation Service for Therapeutic Oligonucleotide
- mRNA-based Vaccine Development Service
- mRNA Sequence Design&Optimization Service
- mRNA Integrity Analysis ServicemRNA Integrity Analysis Service
- mRNA Biodistribution Analysis Service
- DNA Template Preparation Service
- mRNA Purity Analysis Service
- T Cell Cytokine Secretion Analysis Service
- mRNA Modification Service
- mRNA Length Analysis Service
- mRNA Purification Service
- Neutralizing Antibody Assay Service
- mRNA-LNP Formulation and Encapsulation Service
- mRNA Structural Characterization
- mRNA Structural Characterization Service
- mRNA Bioanalysis Service
- mRNA Residual DNA Template Analysis Service
- mRNA Residual Double-Stranded RNA (dsRNA) Analysis Service
- mRNA Size Analysis Service
- mRNA Polydispersity Analysis Service
- mRNA Zeta Potential Analysis Service
- mRNA Lipid Composition Analysis Service
- Oligonucleotide Drug Process and Formulation Development Service
- RNA Drug Process and Formulation Development
- Therapeutic Oligonucleotide Synthesis Service
- Glycobiology Microarray Platform
- Glyco™ Vaccine Development Platform
- Carbohydrate-based Vaccine Development
- Polysaccharide Vaccine Development
- Tumor-Associated Carbohydrate Vaccine Development
- Glycoconjugate Vaccine Development
- Natural Carbohydrate-based Vaccine Development
- Semi-synthetic Carbohydrate-based Vaccine Development
- Fully Synthetic Carbohydrate-based Vaccine Development
- Carbohydrate-based Antibacterial Vaccine Development
- Carbohydrate-based Antifungal Vaccine Development
- Carbohydrate-based Antiparasitic Vaccine Development
- Carbohydrate-based Antiviral Vaccine Development
- Carbohydrate-based Anticancer Vaccine Development
- Carbohydrate-based Antihelmintic Vaccine Development
- Monovalent Carbohydrate-based Vaccine Development
- Polyvalent Carbohydrate-based Vaccine Development
- Carrier Protein Design Service
- Carbohydrate Conjugation Service for Vaccine Development
- Carbohydrate-based Adjuvant Development
- Lipopolysaccharide-based Adjuvant Development
- Bacterial Outer Membrane Vesicles (OMVs)-based Adjuvant Development
- Trehalose Glycolipid-based Adjuvant Development
- Galactosylceramide-based Adjuvant Development
- Peptidoglycan-based Adjuvant Development
- Chitin/Chitosan-based Adjuvant Development
- Inulin-based Adjuvant Development
- Mannans-based Adjuvant Development
- Alginate-based Adjuvant Development
- Saponin-based Adjuvant Development
- α-Glucan-based Adjuvant Development
- Lentinan-based Adjuvant Development
- β-Glucans-based Adjuvant Development
- Deltin-based Adjuvant Development
- Muramyldipeptide-based Adjuvant Development
- Cord Factor-based Adjuvant Development
- Zwitterionic Polysaccharide-based Adjuvant Development
- Novel Plant Polysaccharides-based Adjuvant Development
- Glycoprotein-based Vaccine Development
- Glycopeptide-based Vaccine Development
- Carbohydrate-based Vaccine Development
- Glycogenomics Platform
- Glycogene Editing Service
- Glycogene Delivery Service
- Glycogene Expression Profiling
- Cancer Glycogene Discovery Service
- Glycogene Discovery Service in Cervical Cancer
- Glycogene Discovery Service in Leukemia
- Glycogene Discovery Service in Bladder Cancer
- Glycogene Discovery Service in Colorectal Adenocarcinoma
- Glycogene Discovery Service in Liver Cancer
- Glycogene Discovery Service in Lymphoma
- Glycogene Discovery Service in Breast Cancer
- Glycogene Discovery Service in Prostate Cancer
- Glycogene Discovery Service in Pancreatic Cancer
- Glycogene Discovery Service in Lung Cancer
- Glycogene Discovery Service in Thyroid Cancer
- Glycogene Discovery Service in Ovarian Cancer
- Glycan Display Platform
- Traditional Glycan Display Array
- Natural Oligosaccharide Library Construction Service
- Chemical Synthesis-based Oligosaccharide Library Construction Service
- Enzymatic Synthesis-based Oligosaccharide Library Construction Service
- Modular Synthesis-based Oligosaccharide Library Construction Service
- Oligosaccharide Library Immobilization Service
- Cell-based Glycan Display Array
- Neoglycolipid (NGL) Display Array
- Liquid Glycan Display Array (LiGA)
- Glycophage Display
- N-linked Glycoprotein-based Glycophage Display System Construction Service
- O-linked Glycoprotein-based Glycophage Display System Construction Service
- Glycophage Display-based Glycosylase Genetic Analysis Service
- Glycophag Display-based Glycoarray Service
- Glycophage Display-based Antibody Development Service
- Glycophage Display-based Epitope Mapping Service
- Glycophage Display-based Biomarker Development Service
- De Novo Glycan Display
- Cell-Surface Glycan Editing
- Examining the Effects of Altering Blood Group Antigens on Erythrocyte Cell Surfaces
- Preventing Cellular Rejection During Transplantation
- Modulating Chemical Composition and Physical Parameters of Glycocalyx
- Tailoring Cell Membranes with Biologically Active Glycans
- Targeting Glycosaminoglycan-mediated Growth Factor Signaling to Influence Stem Cell Specification
- Long-term De Novo Glycan Display for Directing Stem Cell Fate
- Traditional Glycan Display Array
- GlycoNano™ Platform
- Glyconanoparticle Development Service
- Techniques for Glyconanoparticle Development
- Carbohydrate-based Nanoparticle Production
- Gold Glyconanoparticle Production
- Silver Glyconanoparticle
- Magnetic Glyconanoparticle
- Quantum Dot (QD) Glyconanoparticle
- Glyconanoparticle Characterization
- PEG Glyconanoparticle
- Carbon-based Glyconanoparticle
- Fluorescent Glyconanoparticle
- Silica Glyconanoparticle
- Liposome Glyconanoparticle
- Glycol Nanohydrogel Development
- Glycol Nanorod
- Glycol Nanotube
- Glycol Nanocrystal/Nanosheet/Nanosphere/Nanofiber
- Glyconanoparticle Preclinical Study
- Glyconanoparticle Formulation
- Glyconanotechnology-based Biosensor Development
- GlycoNano™ Bioink Production for 3D Printing
- Glyconanoparticle Development Service
- Glyco™ Synthesis Platform







